Wall Street brokerages predict that Vistagen Therapeutics Inc (NASDAQ:VTGN) will post ($0.07) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings of ($0.24) per share in the same quarter last year, which would indicate a positive year over year growth rate of 70.8%. The company is expected to announce its next earnings results on Tuesday, February 11th.
According to Zacks, analysts expect that Vistagen Therapeutics will report full year earnings of ($0.40) per share for the current financial year. For the next year, analysts expect that the company will report earnings of ($0.35) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Vistagen Therapeutics.
Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01.
Institutional investors have recently made changes to their positions in the company. LPL Financial LLC acquired a new position in shares of Vistagen Therapeutics during the second quarter worth about $27,000. Wells Fargo & Company MN acquired a new position in shares of Vistagen Therapeutics during the second quarter worth about $31,000. Virtu Financial LLC acquired a new position in shares of Vistagen Therapeutics during the third quarter worth about $65,000. D.A. Davidson & CO. grew its position in shares of Vistagen Therapeutics by 27.3% during the third quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock worth $112,000 after buying an additional 22,500 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in shares of Vistagen Therapeutics by 326.3% during the second quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock worth $96,000 after buying an additional 101,308 shares in the last quarter. 8.75% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ VTGN remained flat at $$0.68 during trading on Friday. The stock had a trading volume of 1,100 shares, compared to its average volume of 477,915. Vistagen Therapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $1.86. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.14 and a quick ratio of 1.14. The company’s 50-day moving average is $0.65 and its two-hundred day moving average is $0.77. The stock has a market cap of $28.54 million, a price-to-earnings ratio of -0.76 and a beta of -0.41.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Article: Analyst Ratings Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.